Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

The trial results are critical, as it brings Eli Lilly's pill one step closer to becoming a new, needle-free alternative for ...

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional $27 billion to build four new manufacturing plants in the United States ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Eli Lilly is expanding its menu of direct-to-consumer healthcare offerings. | Eli Lilly is expanding its menu of ...

Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients without insurance. The company launched 7.5 mg and 10 mg vials of ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Novo Nordisk said yesterday that it’s licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.

Eli Lilly on Tuesday released higher doses of its weight loss drug Zepbound in single-dose vials at as much as half its usual monthly list price to reach more patients without insurance coverage ...

Eli Lilly (LLY 1.80%) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable ...

INDIANAPOLIS: Drugmaker Eli Lilly and Company’s SVP and chief communications officer, Kathryn Beiser, has resigned. Beiser ...